MD Anderson Cancer Center

Site:	MD Anderson Cancer Center	Go to their website
Address:	1505 Holcombe Blvd.
City:	Houston
State:	TX
Zip:	77030
Country:	USA

59 trials at this site

Phase [asc]	Trial	Trial Status	Site Status	Drug	NCT#
	Gastrointestinal Stromal Tumors (GIST) Registry	Completed	Closed	None	NCT00507273
	Symptom Inventory for Gastrointestinal Stromal Tumors	Ongoing, but not recruiting	Closed		NCT01178307
1	Phase I Trial of PX-478	Completed	Closed	PX-478	NCT00522652
1	Phase I Trial of Oral PX-866	Ongoing, but not recruiting	Closed	PX-866	NCT00726583
1	Continuous Dosing of Regorafenib in Patients With Advanced Malignancies	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01117623
1	Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.	Ongoing, but not recruiting	Closed	AUY922	NCT00526045
1	A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors	Ongoing, but not recruiting	Closed	R1507	NCT00560144
1	Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma	Ongoing, but not recruiting	Closed	PXD101	NCT00413075
1	Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer	Ongoing, but not recruiting	Closed	IMC-A12 + CCI-779	NCT00678223
1	IMC-A12 in Combination With Temsirolimus (CCI-779) in Patients With Advanced Cancers	Ongoing, but not recruiting	Closed	IMC-A12 + CCI-779	NCT00678769
1	Phase 1 Study of Intermittent OSI-906 Dosing	Ongoing, but not recruiting	Closed	Linsitinib (OSI-906)	NCT00514306
1	Administration of BIIB028 to Subjects With Solid Tumors	Ongoing, but not recruiting	Closed	BIIB028	NCT00725933
1	A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer	Ongoing, but not recruiting	Closed	BEZ235	NCT00620594
1	Phase I Study of Pazopanib and Vorinostat	Ongoing, but not recruiting	Closed	Pazopanib (Votrient) + vorinostat (Zolinza)	NCT01339871
1	Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BEZ235 + MEK162	NCT01337765
1	Ipilimumab and Imatinib Mesylate in Advanced Cancer	Active, not recruiting	Closed	Imatinib + Ipilimumab	NCT01738139
1	A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BKM120 + GSK1120212	NCT01155453
1	Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer	Ongoing, but not recruiting	Closed	Pazopanib + Trametinib	NCT01438554
1	Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer	Ongoing, but not recruiting	Closed	BAY80-6946 + BAY86-9766	NCT01392521
1	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors	Terminated	Closed	Trametinib + Palbociclib	NCT02065063

MD Anderson Cancer Center

59 trials at this site

Page 1 of 3 | Next | Last